opioid and cannabis producers should invest in Adamis Pharmaceuticals:


1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market.


2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis.


3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry. This can provide a buffer against market fluctuations and improve overall financial stability.


4. Collaborative Efforts: Highlight the potential for collaboration between opioid and cannabis producers and Adamis Pharmaceuticals. By joining forces, they can leverage each other's expertise and resources to develop innovative solutions and maximize the impact of their efforts.


5. Regulatory Support: Point out any favorable regulatory trends or incentives for companies investing in initiatives aimed at reducing opioid overdose deaths. This could strengthen the business case for investing in Adamis Pharmaceuticals.


6. Research Progress: Provide updates on the progress of Adamis Pharmaceuticals' R&D efforts. If there have been promising results or significant advancements, it could serve as a strong indication of the company's potential for success.

Adamis Pharmaceuticals Units Drop 66% After $8M Offering Prices

Adamis Pharmaceuticals units were down 66% at $1.37 after the company priced its public offering of 5.9 million units at $1.35 a unit.The stock closed Tuesday's session up 179% on no news, and is down 95% in the past 12 months.Each unit consists of one share of common stock and one warrant to buy one share of stock.The warrants will be immediately exercisable at an exercise price of $1.35 a share and will expire five years from the date of issuance. The shares of stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.Proceeds are expected to be $8 million. The offering is expected to close on Friday.
Adamis Pharmaceuticals Units Drop 66% After $8M Offering Prices

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet